GW 6471
目录号 : GC14187
GW 6471 是一种有效的双重 PPARα/γ 拮抗剂，其具有体内外抗增殖活性。GW 6471与 PPARα 和 PPARγ 的结合亲和力的IC50 值分别为95.3 ± 42.0 nM 和39.4 ± 18.2 nM。GW 6471可用于癌症的研究。
Cas No.:880635-03-0
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1]: | |
Cell lines | HNPGL cells (PTJ64i and PTJ86i) |
Preparation Method | A stock solution of GW 6471 (70 mM) was prepared in DMSO, with a final DMSO concentration of 0.16% in the experiments.After incubation with GW 6471 (3 to 24 μM) for 72 hours, the cell viability was measured by MTT assay. |
Reaction Conditions | 3 to 24 μM,72 hours |
Applications | GW 6471 significantly reduced cell viability in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Caki-1 cell xenograft mouse model |
Preparation Method | After the tumor diameter reached about 5 mm, GW 6471 (20 mg/kg) was injected intraperitoneally every other day for 4 weeks. |
Dosage form | 20 mg/kg, once every two days, 4 weeks, i.p. |
Applications | GW 6471 was able to inhibit tumor growth in vivo, and GW 6471 did not adversely affect the renal and liver functions of mice. |
References: | |
GW 6471 is a potent dual PARα/γ antagonist with anti-proliferative activity in vivo and in vitro. The IC50 values of GW 6471 binding affinity to PPARα and PPARγ are 95.3 ± 42.0 nM and 39.4 ± 18.2 nM, respectively[1]. GW 6471 can be used in cancer research[1-3].
GW 6471 inhibits the growth (0.5 μM to 8 μM), migration and invasion (0.5 μM to 10 μM) of human mesothelioma cells and, at higher concentrations, reduces the viability of human mesothelioma cell line VGE62 and murine mesothelioma cell lines AB1 and AE17[1]. GW 6471 reduces HNPGL cell viability and growth by inducing cell cycle arrest and caspase-dependent apoptosis with IC50 values of 10 μM and 16 μM in PTJ64i and PTJ86i cells, respectively. The effect of GW 6471 on HNPGL cells is associated with inhibition of the PI3K/GSK3β/β-catenin signaling pathway[2].
GW 6471 (20 mg/kg) inhibited tumor growth in Caki-1 cell xenograft mouse models and the expression of c-Myc in mouse tumor tissues. No toxicity was observed at a dose of 20 mg/kg, and renal and liver functions were not adversely affected[3]. Medial prefrontal cortex injection of GW6471 (10 μg) in rats delayed the onset of the early second phase of formalin-induced nociceptive behavior[4].
References:
[1] Morales M L O, Rinaldi C A, de Jong E, et al. PPARα and PPARγ activation is associated with pleural mesothelioma invasion but therapeutic inhibition is ineffective[J]. Iscience, 2022, 25(1).
[2] Florio R, De Lellis L, di Giacomo V, et al. Effects of PPARα inhibition in head and neck paraganglioma cells[J]. PLoS One, 2017, 12(6): e0178995.
[3] Abu Aboud O, Donohoe D, Bultman S, Fitch M, Riiff T, Hellerstein M, Weiss RH. PPARα inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth. Am J Physiol Cell Physiol. 2015 Jun 1;308(11):C890-8.
[4] Okine B N, Rea K, Olango W M, et al. A role for PPAR α in the medial prefrontal cortex in formalin‐evoked nociceptive responding in rats[J]. British journal of pharmacology, 2014, 171(6): 1462-1471.
GW 6471 是一种有效的双重 PPARα/γ 拮抗剂，其具有体内外抗增殖活性。GW 6471与 PPARα 和 PPARγ 的结合亲和力的IC50 值分别为95.3 ± 42.0 nM 和39.4 ± 18.2 nM[1]。GW 6471可用于癌症的研究[1-3]。
GW 6471 可以抑制人间皮瘤细胞的生长（0.5 μM 至 8 μM）、迁移和侵袭（0.5 μM 至 10 μM），在较高浓度下还降低了人间皮瘤细胞系VGE62以及鼠间皮瘤细胞系 AB1 和 AE17 的活力[1]。GW 6471 通过诱导细胞周期停滞和 caspase 依赖性细胞凋亡来降低 HNPGL 细胞活力和生长，在PTJ64i 与PTJ86i 细胞中的 IC50 分为 10 μM和16 μM，并且GW 6471 对 HNPGL 细胞的作用与抑制 PI3K/GSK3β/β-catenin 信号通路有关[2]。
GW 6471（20 mg/kg）可抑制Caki-1细胞异种移植小鼠模型中肿瘤的生长及小鼠肿瘤组织中c-Myc 的表达，剂量为20 mg/kg时未观察到毒性，肾功能和肝功能未受到不利影响[3]。在大鼠内侧前额叶皮质（mPFC）内注射GW6471（10 μg）可使福尔马林诱发的伤害性行为的早期第二阶段延迟发作[4]。
| Cas No. | 880635-03-0 | SDF | |
| 化学名 | (S,Z)-N-(3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-2-((4-oxo-4-(4-(trifluoromethyl)phenyl)but-2-en-2-yl)amino)propyl)propionamide | ||
| Canonical SMILES | CC1=C(N=C(C2=CC=CC=C2)O1)CCOC3=CC=C(C[C@H](N/C(C)=C\C(C4=CC=C(C(F)(F)F)C=C4)=O)CNC(CC)=O)C=C3 | ||
| 分子式 | C35H36F3N3O4 | 分子量 | 619.67 |
| 溶解度 | DMF: 20 mg/ml,DMF:PBS(pH7.2) (1:2): 0.33 mg/ml,DMSO: 11 mg/ml,Ethanol: 10 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.6138 mL | 8.0688 mL | 16.1376 mL |
| 5 mM | 0.3228 mL | 1.6138 mL | 3.2275 mL |
| 10 mM | 0.1614 mL | 0.8069 mL | 1.6138 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。